Last reviewed · How we verify
TNB-383B
At a glance
| Generic name | TNB-383B |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (PHASE1, PHASE2)
- A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (PHASE1, PHASE2)
- Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNB-383B CI brief — competitive landscape report
- TNB-383B updates RSS · CI watch RSS
- AbbVie portfolio CI